rocky89 / iStockphoto.com
10 January 2018Big Pharma
Allergan tries to escape Restasis IPRs
Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
8 January 2018 The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018 Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018 The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
Editor's picks
Editor's picks
Americas
8 January 2018 The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018 Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018 The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
Americas
8 January 2018 The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018 Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018 The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.